Featured Research

from universities, journals, and other organizations

New Test Identifies Aggressive And Less Aggressive Prostate Cancers

Date:
June 12, 2002
Source:
University Of Minnesota
Summary:
A simple test can be used to identify patients with the most aggressive prostate cancers, even among patients whose tumors are at the same stage, according to research at the University of Minnesota.

MINNEAPOLIS / ST. PAUL -- A simple test can be used to identify patients with the most aggressive prostate cancers, even among patients whose tumors are at the same stage, according to research at the University of Minnesota.

Related Articles


The degree to which prostate cancers have progressed is determined by the Gleason grading system, which is based on the shape and microscopic appearance of tumors. Patients with higher grades of tumor are in more advanced stages of the disease, but the grade does not tell how aggressively the tumors have been growing or metastasizing. The new test was developed by cancer researcher Akhouri Sinha, a professor of genetics, cell biology, and development, faculty member of the University of Minnesota Cancer Center and research scientist at the Minneapolis Veterans Affairs Medical Center, and his colleagues. The work will be published in the June 15 issue of Cancer. Donald Gleason, who developed the Gleason grading system, is a co-author.

After skin cancer, prostate cancer is the most common form of cancer in U.S. men, according to National Cancer Institute statistics. More than a quarter of men diagnosed with cancer have prostate cancer. The disease strikes black men more often than white; Asian and American Indian men are affected less often. The Gleason grading system assigns tumors a score between two and 10, with 10 being the most advanced cancer. Patients with a Gleason score from seven to 10 have a higher risk of dying of prostate cancer than those with lower scores, but some patients with higher scores outlive some with lower scores.

"This means that within any score, there are biologically aggressive and less aggressive forms of cancer," said Sinha. "This makes it more difficult to predict outcomes for individual patients."

In order to invade surrounding tissue and escape to blood vessels, cancer cells produce high levels of an enzyme called cathepsin B (CB), which destroys proteins in the connective tissue that holds cells in place. But cells also produce natural inhibitors of CB called stefins. The researchers reasoned that prostate tumors in which levels of inhibitors were equal to or higher than CB would be less aggressive. But if CB was higher, the tumor would be more likely to spread.

Working with prostate surgery samples from 97 prostate cancer patients and eight patients with a benign enlargement of the prostate, the researchers measured the ratio of CB to the inhibitor stefin A in prostate tissue. They used tissue from Gleason grade 6 tumors, which appear relatively homogeneous under the microscope. They found that the ratio of CB to stefin A was significantly higher in patients whose cancer had spread to one or more pelvic lymph nodes than in patients whose nodes were clear.

"The ratio of CB to stefin A reveals differences in tumors that are not visible under the microscope," said Sinha. "If this test were done on tumors of newly diagnosed patients, we would have an indication of which cancers were most aggressive, and we could give those patients aggressive treatment. Those patients whose tumors show ratios of one, or less than one, may require less aggressive treatment. This approach could also be used for breast and colon cancer."

The work was supported by the U.S. Public Health Service and the Research Service of the Minneapolis Veterans Affairs Medical Center.

In previous work, Sinha devised a treatment for prostate cancer that zeroes in on prostate specific antigen, or PSA. High blood levels of PSA are a common first signal of prostate cancer. Prostate cells, including prostate cancer cells, display PSA on their outer surfaces. Working with mice, Sinha used a treatment that consisted of an antibody to PSA coupled to an anti-cancer drug. The antibody attached to PSA molecules on prostate cells, which prompted the cells to absorb the antibody-drug compound. In metabolizing the compound, the cells split off the drug, which killed the cells. The antibody-drug compound attached preferentially to PSA on prostate cells rather than to circulating PSA in the blood or to any other organ. Sinha said almost any chemotherapeutic agent could be coupled to the antibody. That work is ready to be tested in a phase 1 clinical trial, for which Sinha seeks funding.


Story Source:

The above story is based on materials provided by University Of Minnesota. Note: Materials may be edited for content and length.


Cite This Page:

University Of Minnesota. "New Test Identifies Aggressive And Less Aggressive Prostate Cancers." ScienceDaily. ScienceDaily, 12 June 2002. <www.sciencedaily.com/releases/2002/06/020612072926.htm>.
University Of Minnesota. (2002, June 12). New Test Identifies Aggressive And Less Aggressive Prostate Cancers. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2002/06/020612072926.htm
University Of Minnesota. "New Test Identifies Aggressive And Less Aggressive Prostate Cancers." ScienceDaily. www.sciencedaily.com/releases/2002/06/020612072926.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins